Can maraviroc help HIV patients whose immune systems lag behind?
NCT ID NCT00944541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the drug maraviroc to standard HIV treatment could help improve immune function in people whose CD4 counts remain low even when the virus is well-controlled. It involved 60 HIV-positive adults with low CD4 counts and little recent immune improvement. Participants took maraviroc for 24 weeks, and researchers monitored their immune recovery and safety for up to 48 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
French National Agency for Research on AIDS and Viral Hepatits
Paris, 75013, France